ARD-2128

ARD-2128

• CAS Number: 2222111-87-5
• UNSPSC Description: ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer[1].
• Target Antigen: Androgen Receptor; PROTACs
• Type: Reference compound
• Related Pathways: PROTAC;Vitamin D Related/Nuclear Receptor
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ard-2128.html
• Purity: 99.40
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(N[C@H]1C(C)(C)[C@H](OC2=CC=C(C#N)C(Cl)=C2)C1(C)C)C3=CC=C(N4CCN(CC5CCN(C6=CC7=C(C(N(C(CC8)C(NC8=O)=O)C7=O)=O)C=C6)CC5)CC4)C=C3
• Molecular Weight: 820.37
• References & Citations: [1]Han X, et al. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer [published online ahead of print, 2021 Aug 25]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00882.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: No Development Reported